MVA Members

Immunicum

Immunicum is developing novel immuno-oncology therapies against a range of solid tumors. The approach is based on allogeneic dendritic cells that are designed to stimulate a personalized anti-tumor immune response in each patient. The Company’s lead compound, ilixadencel is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors.